These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Beta-blockers and diabetes: the bad guys come good. Cruickshank JM Cardiovasc Drugs Ther; 2002 Sep; 16(5):457-70. PubMed ID: 12652116 [TBL] [Abstract][Full Text] [Related]
45. Management of multiple risk factors for coronary heart disease in patients with hypertension. Poulter N Am Heart J; 1991 Jan; 121(1 Pt 2):246-9; discussion 249-50. PubMed ID: 1670743 [TBL] [Abstract][Full Text] [Related]
46. Pathophysiologic and pharmacotherapy considerations in the management of the black hypertensive patient. Cook CA Am Heart J; 1988 Jul; 116(1 Pt 2):288-95. PubMed ID: 2899388 [TBL] [Abstract][Full Text] [Related]
47. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs. Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022 [TBL] [Abstract][Full Text] [Related]
48. Retrospective and prospective research on hypertension-related end-organ damage. Perloff D J Cardiovasc Pharmacol; 1994; 24 Suppl A():S1-5. PubMed ID: 7603071 [TBL] [Abstract][Full Text] [Related]
49. [Drug therapy of arterial hypertension. Reflections and suggestions]. Franchi F; Fabbri G Clin Ter; 1989 May; 129(4):299-313. PubMed ID: 2527124 [TBL] [Abstract][Full Text] [Related]
50. [Coronary disease risk and prevalence of heart disease in primary care patients with hypertension and renal disease]. Cosín-Aguilar J; Hernándiz-Martínez A; Arístegui-Urrestarazu R; Masramón-Morell X; Aguilar-Llopis A; Rodríguez-Padial L; Zamorano-Gómez JL; Rev Esp Cardiol; 2006 Oct; 59(10):1026-32. PubMed ID: 17125712 [TBL] [Abstract][Full Text] [Related]
51. Hypertension and insulin resistance. Prichard BN; Smith CC; Sen S; Betteridge DJ J Cardiovasc Pharmacol; 1992; 20 Suppl 11():S77-84. PubMed ID: 1284147 [TBL] [Abstract][Full Text] [Related]
54. Role of hypertension in coronary artery disease. Weber MA Am J Nephrol; 1996; 16(3):210-6. PubMed ID: 8739880 [TBL] [Abstract][Full Text] [Related]
55. Antihypertensive therapy in dyslipidemic men. Effects on coronary heart disease incidence and total mortality. Mänttäri M; Tenkanen L; Manninen V; Alikoski T; Frick MH Hypertension; 1995 Jan; 25(1):47-52. PubMed ID: 7843752 [TBL] [Abstract][Full Text] [Related]
56. What have we learned from the current trials? Abbott KC; Bakris GL Med Clin North Am; 2004 Jan; 88(1):189-207. PubMed ID: 14871059 [TBL] [Abstract][Full Text] [Related]
57. Treatment of obesity hypertension and diabetes syndrome. Zanella MT; Kohlmann O; Ribeiro AB Hypertension; 2001 Sep; 38(3 Pt 2):705-8. PubMed ID: 11566961 [TBL] [Abstract][Full Text] [Related]
58. Challenges in the Management of Hypertension in Older Populations. Pont L; Alhawassi T Adv Exp Med Biol; 2017; 956():167-180. PubMed ID: 27815929 [TBL] [Abstract][Full Text] [Related]
59. The case for beta-blockers as first-line antihypertensive therapy. Cruickshank JM J Hypertens Suppl; 1992 Jun; 10(3):S21-7. PubMed ID: 1353111 [TBL] [Abstract][Full Text] [Related]